# Emerging pandemic leishmaniasis: How virulent are the parasites?
Quaglee Dragontacos


## Abstract

The recent increase in human immunodeficiency virus (HIV) associated infections in developing countries of poor settings is an ever-expanding threat to our healt. The global increase in HIV related morbidity and mortality is a consequence of the growing number of immunocompromised patients with low CD4 and CD8 T-cell counts. It is becoming clear that HIV is a rapidly evolving disease entity with increasing prevalence in sub-Saharan Africa with increasing prevalence rates of other diseases, including tuberculosis. Most research on HIV/AIDS has focused on the diagnosis of HIV infection in the late 1990s and early 2000s, with few studies into the epidemiology, clinical characteristics, and treatment efficacy of HIV/AIDS in resource-limited areas. The objective of this review was to provide a review of the current knowledge of the epidemiology, treatment, and outcomes of HIV/AIDS in sub-Saharan Africa.

We first searched MEDLINE and Duren ACTA for studies reporting the etiologies, outcomes, and treatments of HIV/AIDS in sub-Saharan Africa between 2000 and 2017. We also searched Cryptococcus neoformans International, C. gondii International, C. serotype 4, and Pneumocystis jirovecii International, for studies reporting outcomes of treatment discontinuation or relapse of HIV in adults and children in sub-Saharan Africa. Data on patient characteristics, treatment history, and outcomes of HIV/AIDS in sub-Saharan Africa were also collected.

Data were collected in 2000 and 2002 from patients enrolled in a UK public health service seeking programme for patients with HIV/AIDS with CD4 counts between 2000 and 2017. Data were analyzed using univariate, multivariate, and multivariable. Outcomes were recorded; treatment discontinuation, and treatment vs follow-up outcomes in adults and children.

Data from 1077 patients were available for 6 studies. The mean age was 37.4 years, and 67.1% were female. Treatment discontinuation (23.4%) occurred in 733 patients; 554 (11.9%) had received antiretroviral therapy (ART) within 12 months. The most common presentations were central venous access (12%) followed by peritoneal dialysis (6.9%) and HIV-related cytomegalovirus (6.5%). The treatment discontinuation rate was 53.2%.


## Introduction

More recently, the availability of an entire collection of Malassezia genome sequences (Strobel and Daisy, 2005), which were not related to the host, gave us the opportunity to perform comparative analyses of the genomes of Malassezia species in order to answer the question of how virulence-related virulence traits are manifesting in the Malassezia genu. These genomes were assembled and compared with the genomes of the closely related species Malassezia restricta and M. oryzae and their close relative M. oryzae (DiCosmo et al., 2009; Jaspersen et al., 2012). The genomes of these closely related Malassezia species are now available and exhibit extraordinary variability, with some species exhibiting high virulence and invasion capacity (DiCosmo et al., 2009; Jaspersen et al., 2012). The genomes of Malassezia globosa and M. oryzae have a similar genome architecture, with the exception of the large subunit ribosomal RNA (LSU rRNA), which has been recently identified as a marker for virulence (Girard et al., 2006; Jaspersen et al., 2012).

In the Malassezia genus, numerous parasites infect humans and other mammals. Infection by Malassezia globosa occurs in the form of a zoonotic infection, a disease that is caused by the dimorphic dimorphic fungus M. oryzae. The dimorphic fungus is transmitted by the aerosolized spores of the infectious mycelium. The spores can survive and proliferate in the phagolysosome and cause a localized infection of the lung and other organs (Malaviya and Jaspersen, 2003). Infection by the dimorphic fungus M. oryzae begins when the infectious mycelium becomes more and more enlarged, and then increases in size and eventually causes a fatal infection of the lung and other organs (Malaviya and Jaspersen, 2003). The pathogen has a worldwide distribution, and the availability of the M. oryzae genome sequence opens new possibilities for studying its pathogenicity and virulence in different hosts (Malaviya and Jaspersen, 2003).

The Malassezia genus has a complex history that is characterized by a variety of pathogenicity mechanisms.


## Methods
The animal was observed every day and the numbers of animals counted were the average number of animals counted in that da. The parasite burdens in the infected animals infected with infectious strains were calculated as previously described [20].

2.5. Statistical Analysis
The differences between two groups were analyzed using one-way ANOVA with Tukey’s multiple-comparison test. Differences between two groups were compared using the Student’s t-test. The data were analyzed by the nonparametric Mann-Whitney test using the statistical program GraphPad Prism Version 7.0 (GraphPad Software, San Diego, CA, USA).

2.6. Cytotoxicity
The cytotoxic effects of the H_2O_2 treatment were determined by the absorbance of H_2O_2 at 405 nm using a microplate reader (Multiskan EX, Thermo Fisher Scientific, Waltham, MA, USA) [21]. The concentration of H_2O_2 used was 0.125 mM.

2.7. Biofilm Formation
The biofilm formation assay was performed as described previously [22]. The biofilm formation in the presence of H_2O_2 and CpG were determined by the biofilm formation assay according to the method described previously [23]. The biofilm formation was measured by monitoring the biofilm growth on MDA plates (Molecular Bioscience, San Diego, CA, USA) for 24 h and 48 h. The biofilm of the blank plates was used as a positive control.

2.8. Determination of Non-Targeted Cell Lines
The cells of the cell lines CD11c^+ and CD45.1^- were used to determine the non-targeted cell lines (NTCs) using the EZCycle^TM Array (BioXCell, Inc., USA) with a Gene Ontology (GO) enrichment in the metabolic pathway of the most active molecules.


## Results
Is the leishmaniasis population in the .S. (Table 1) also different than that of the 1930s and 1940s?

As in the U.S. and other countries, the U.S. is a model of future disease, but there is not enough data to demonstrate that the U.S. is a model of disease. As in the U.S., the U.S. is a model of the future, and the U.S. has a poor picture of disease, we are interested in studying the U.S. in terms of virulence, and the U.S. is a model of disease.

The U.S. is a model of disease
The U.S. is a model of disease. It is characterized by several historical phenomena, such as its emergence in the late 19th and early 20th centuries, its introduction in the early 20th century, the disappearance of the land use and industrial dominance, and the recent history of mass incarceration. The U.S. is characterized by the following: (i) The rate of starvation in the U.S. is estimated at a rate of about 1.8 g/m^2/year. (ii) The rate of human mortality is estimated at a rate of about 1.4/m^2/year. (iii) The rate of G. mellonella infection in the U.S. is estimated at a rate of about 1.4/m^2/year. (iv) The U.S. is characterized by the following: (i) The rate of G. mellonella infection is estimated at a rate of about 1.3/m^2/year. (ii) The rate of G. mellonella infection is estimated at a rate of about 1.4/m^2/year. (iii) The rate of G. mellonella infection is estimated at a rate of about 1.4/m^2/year. (iv) The U.S. is characterized by the following: (i) The rate of G. mellonella infection is estimated at a rate of about 1.3/m^2/year. (ii) The rate of G. mellonella infection is estimated at a rate of about 1.3/m^2/year. (iii) The rate of G. mellonella infection is estimated at a rate of about 1.


## Discussion
The disease was endemic in both Australia and Australi. The current outbreak is the first report of a second case of infection following the first one in Australia.

The leishmaniasis outbreak was largely associated with the War Office infection, which was responsible for the outbreak in South Australia. In South Australia, the leishmaniasis outbreak began in July 2008, and the outbreak was most likely to have been the result of the War Office infection. The outbreak occurred in the Early 2000s, when the War Office infection was started. The outbreak was accompanied by high mortality and morbidity and was associated with the emergence of opportunistic infections, including leishmaniasis, the introduction of new drugs, and the introduction of new vaccines.

The current outbreak has a relatively small population of infected individuals. However, it is estimated that there were more than 4 million people living with HIV in Australia between 1997 and 2000. A population study in the late 2000s estimated that between 20 and 35% of the people living with HIV in Australia had acquired HIV during this period [4]. In addition, the Infectious Disease Society of Victoria (IDSA) estimates that between 2000 and 2014, the number of patients living with HIV in Victoria reached a peak of 4.3 million [5].

The current outbreak of leishmaniasis in Australia has some characteristics that might be responsible for the emergence of the outbreak. For example, the geographic location of the outbreak might have affected the incidence of infection and survival of leishmaniasis in the region. Other factors that could be responsible for the emergence of Leishmania in Australia might be the introduction of drugs into the environment.

The outbreak is largely associated with the War Office infection, which was responsible for the outbreak in South Australia. The War Office infection was introduced in Australia in July 2008, and the outbreak was most likely to have been the result of the War Office infection. The outbreak was followed by high mortality and morbidity and was associated with the emergence of opportunistic infections, including leishmaniasis, the introduction of new drugs, and the introduction of new vaccines.

The current outbreak is associated with the introduction of drugs into the environment. This study suggests that the introduction of drugs into the environment might have contributed to the emergence of Leishmania.
